Publication | Open Access

FP03.02 Interim Analysis of Neoadjuvant Chemoradiotherapy and Durvalumab for Potentially Resectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Surgical OncologyNeoadjuvant ChemoradiotherapyFp03.02 Interim AnalysisMedicineBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyLung CancerRadiologyHealth Sciences